Make no mistake: The one long-term resolution to the COVID-19 pandemic is a protected and efficient vaccine. The present gives attention to figuring out efficient therapies, whereas vital, serve solely as a brief Band-Aid.
We don’t know, but if hydroxychloroquine, remdesivir, or any of the opposite repurposed medicine presently being examined in a blitzkrieg of rapidly designed scientific trials are going to work and save lives. It’s extremely doubtless that almost all of them, if not all of them, will fail or be solely marginally useful.
Plasma obtained from individuals who have overwhelmed COVID-19, crammed with virus-neutralizing antibodies, is likelier to be of some assist. Quantifying its usefulness and discovering a strategy to scale it up as a remedy would require overcoming quite a few logistical and regulatory complications.
We want a vaccine. Disease prevention at all times beats illness therapy, each in stopping human struggling and lowering well-being care prices. It’s seemingly that scientists will develop an efficient vaccine to finish this pandemic; however it could take a very long time to get there.
Three a long time after AIDS started its march around the globe, we nonetheless don’t have a vaccine to forestall it. And whereas there are efficient therapies, they’re expensive (PrEP, for instance, is unaffordable in lots of countries), include vital negative effects, and don’t (usually) forestall the additional unfold of the illness.
By serving to quench the COVID-19 pandemic, pharma can have received the lottery. Its ship could have available in with a package deal bearing the Golden Ticket. Let’s see if the trade can reap the benefits of this as soon as-in-a-lifetime alternative to restore the reputation it has spent the previous half-century sullying.